Vargas-Alarcón Gilberto, Reyes-Barrera Juan, Cardoso-Saldaña Guillermo, Antonio-Villa Neftali, Fuentevilla-Álvarez Giovanny, Fragoso José Manuel, Posadas-Sánchez Rosalinda
Department of Molecular Biology and Research Direction, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Department of Endocrinology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Biomol Biomed. 2025 Aug 5;25(9):2139-2147. doi: 10.17305/bb.2025.11950.
Dipeptidyl peptidase-4 (DPP4) concentrations are known to correlate with nonalcoholic fatty liver (FL), which is also associated with subclinical atherosclerosis (SA). This study aimed to determine whether DPP4 concentrations and the DPP4 rs17574 polymorphism are associated with FL in individuals with SA. The study included 378 participants with SA, of whom 143 had FL and 235 did not. DPP4 serum concentrations were measured using a Bioplex system, and DPP4 rs17574 genotypes were determined using TaqMan assays. Logistic regression was used to assess the relationships between FL, DPP4 concentrations, and rs17574 genotypes. Overall, DPP4 concentrations did not differ significantly between individuals with and without FL. No significant differences in DPP4 levels were observed among DPP4 genotypes in the total sample. However, within the FL group, significant differences in DPP4 concentration were observed across genotypes: AA genotype (134 [106-175] ng/mL), AG genotype (128 [114-149] ng/mL), and GG genotype (80 [71-117] ng/mL); P = 0.019. The DPP4 rs17574 polymorphism was associated with FL under a recessive model (P = 0.037). DPP4 concentration was also significantly associated with FL: the likelihood of presenting with FL increased by 6.2% for every 10 ng/mL increase in DPP4 levels (P = 0.009). These findings suggest that DPP4 concentration may serve as a biochemical risk marker for FL in individuals with SA. Moreover, the rs17574 polymorphism may influence DPP4 protein levels, particularly in those with FL. To our knowledge, this is the first study to describe an association between DPP4 concentration, the rs17574 polymorphism, and FL. Assessing DPP4 levels may offer a novel and effective strategy for risk stratification of FL in SA populations.
已知二肽基肽酶 -4（DPP4）浓度与非酒精性脂肪肝（FL）相关，而非酒精性脂肪肝又与亚临床动脉粥样硬化（SA）有关。本研究旨在确定DPP4浓度及DPP4 rs17574多态性是否与患有SA的个体的FL相关。该研究纳入了378名患有SA的参与者，其中143人患有FL，235人未患FL。使用Bioplex系统测量DPP4血清浓度，并使用TaqMan分析确定DPP4 rs17574基因型。采用逻辑回归评估FL、DPP4浓度和rs17574基因型之间的关系。总体而言，患有和未患FL的个体之间DPP4浓度无显著差异。在总样本中，各DPP4基因型的DPP4水平未观察到显著差异。然而，在FL组中，不同基因型的DPP4浓度存在显著差异：AA基因型（134 [106 - 175] ng/mL）、AG基因型（128 [114 - 149] ng/mL）和GG基因型（80 [71 - 117] ng/mL）；P = 0.019。在隐性模型下，DPP4 rs17574多态性与FL相关（P = 0.037）。DPP4浓度也与FL显著相关：DPP4水平每升高10 ng/mL，出现FL的可能性增加6.2%（P = 0.009）。这些发现表明，DPP4浓度可能作为患有SA的个体发生FL的生化风险标志物。此外，rs17574多态性可能影响DPP4蛋白水平，特别是在患有FL的个体中。据我们所知，这是第一项描述DPP4浓度、rs17574多态性与FL之间关联的研究。评估DPP4水平可能为SA人群中FL的风险分层提供一种新的有效策略。
